ClinicalTrials.gg

Program

HS-20117

A development code. Also written as “HS-20117 combined Platinum-containing chemotherapy”, “HS-20117+CAPEOX” and “HS-20117+FOLFIRI”.

In Hansoh Pharmaceutical Group's pipeline, EGFR/c-MET bispecific, PM1080. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Hansoh Pharmaceutical Group.

Furthest: phase 3, since May 12, 20243 company-led studies, 3 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group33 open or runningphase 3since May 12, 2024Jun 26, 2023none ahead
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-20117 (EGFR/c-MET bispecific, PM1080), phase 1, as of Aug 26, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 26, 2023First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05940116 · 322 planned · China
  2. May 12, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06417008 · 1,080 planned · China
  3. Sep 29, 2024Phase 1 study in Carcinoma, Non-Small-Cell LungNCT06621563 · 780 planned · China

TargetBeta

“EGFR/c-MET bispecific, PM1080”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
amivantamabruleJohnson & Johnsonphase 316
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
pamvatamigruleBetta Pharmaceuticalsphase 25
TQB2922Sino Biopharmaceuticalphase 25
TQB6411Sino Biopharmaceuticalphase 23
Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101ruleVelaVigo Caymanphase 21
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412ruletavotek-biotherapeuticsphase 12
HS-20122Hansoh Pharmaceutical Groupphase 12
Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902ruleBeOne Medicinesphase 11
Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446Johnson & Johnsonphase 11
HLX48Fosun Pharmaphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06621563Carcinoma, Non-Small-Cell Lung · China1RecruitingMar 30, 2026780
NCT06417008Carcinoma, Non-Small-Cell Lung · China3RecruitingJun 1, 20261,080
NCT05940116Carcinoma, Non-Small-Cell Lung · China1Not yet recruitingJul 30, 2025322

How it is read

Names in the registry

  • “HS-20117”, 2 entries
  • “HS-20117 combined Platinum-containing chemotherapy”, 1 entry
  • “HS-20117+CAPEOX”, 1 entry
  • “HS-20117+FOLFIRI”, 1 entry
  • “HS-20117+mFOLFOX6”, 1 entry

Codes read as this program: HS20117.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.